ReviewPathologica2021
Neuroendocrine neoplasms of the appendix, colon and rectum.
Review in Pathologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- NANETS Guidelines for the diagnosis and management of stage I-III rectal neuroendocrine tumors.Endocrine-related cancer · 2026Guideline
- [Rectal neuroendocrine tumors of the rectum: update on endoscopic and surgical treatment].Chirurgie (Heidelberg, Germany) · 2026Review
- Analysis of the efficacy and safety of endoscopic full-thickness resection in the treatment of rectal neuroendocrine tumors.Frontiers in medicine · 2026Article
- Novel concepts of cell-of origin in neuroendocrine neoplasms.Virchows Archiv : an international journal of pathology · 2026Review
- Prognostic impact of primary tumor resection and nomogram development for survival prediction in colonic neuroendocrine carcinoma patients with liver metastasis: a SEER database-based study.Discover oncology · 2025Article
- Unusual histopathologic findings of appendectomy specimens: A retrospective study of cases at Jordan University Hospital over the last decade (2015-2024).Saudi medical journal · 2025Article
- The Genomic Topography of Appendiceal Cancers: Our Current Understanding, Clinical Perspectives, and Future Directions.Cancers · 2025Review
- Predictors of All-Cause In-Hospital Mortality in Patients With Malignant Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.World journal of oncology · 2025Article
- Radiotherapy versus no radiotherapy for rectal neuroendocrine carcinoma patients treated with surgery and chemotherapy: a population-based cohort study.Discover oncology · 2025Article
- Survival outcomes of local versus radical resection for appendiceal neuroendocrine tumors: a population-based study.Translational cancer research · 2025Article
- Incidence trends and relative survival of colorectal neuroendocrine neoplasms: A population-based study using German cancer registry data.International journal of cancer · 2025Article
- Clinical features and prognostic analysis of 14 cases of appendiceal mixed neuroendocrine-non-neuroendocrine tumors with peritoneal pseudomyxoma.World journal of surgical oncology · 2025Article
- Mixed neuroendocrine-non-neuroendocrine neoplasm of the colon treated with laparoscopic resection and adjuvant chemotherapy: a case report.Clinical journal of gastroenterology · 2025Article
- Gastroesophageal Neuroendocrine Tumors: Outcomes and Management.Journal of clinical medicine · 2025Review
- GATIS score: An innovative prognostic score for rectal neuroendocrine neoplasms.World journal of gastroenterology · 2025Article
- Development of a Nomogram-Based Online Calculator for Predicting Cancer-Specific Survival in Patients With Digestive Tract Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms (MiNENs): An Analysis of the SEER Database.Cancer reports (Hoboken, N.J.) · 2025Article
- LSD1 and CoREST2 Potentiate STAT3 Activity to Promote Enteroendocrine Cell Differentiation in Mucinous Colorectal Cancer.Cancer research · 2025Article
- Rectal neuroendocrine tumor during anorectal surgery: three case reports and a review of the literature.Frontiers in oncology · 2025Article
- Outcome of Endoscopic Resection of Rectal Neuroendocrine Tumors ≤ 10 mm.Diagnostics (Basel, Switzerland) · 2024Article
- Factors Affecting Survival Outcomes in Neuroendocrine Tumor of the Appendix over the Past Two Decades.Diseases (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine neoplasms of the appendix, colon and rectum are classified according to the most recent WHO classification as neuroendocrine tumors (NET), neuroendocrine carcinomas (NEC) and mixed neuroendocrine-non neuroendocrine neoplasms (MiNENs). NECs and MiNENs are aggressive neoplasms requiring multimodal treatment strategies. By contrast, NETs are, in most cases, indolent lesions occurring as incidental findings in the appendix or as polyps in the rectum. While most appendiceal and rectal NETs are considered relatively non-aggressive neoplasms, a few cases, may show a more aggressive clinical course. Unfortunately, clinical/pathological characteristics to select patients at high risk of recurrence/metastases are poorly consolidated. Diagnosis is generally easy and supported by the combination of morphology and immunohistochemistry. Differential diagnostic problems are for NECs/MiNENs with poorly differentiated adenocarcinomas, when immunohistochemical neuroendocrine markers are not obviously positive, whereas for NETs they are represented by the rare appendiceal tubular and clear cell variants (which may be confused with non-neuroendocrine cancers) and rectal L-cell tumors which may be chromogranin negative and prostatic marker positive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.